For the quarter ending 2025-09-30, RNA had $106,251K increase in cash & cash equivalents over the period. -$156,885K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -174,442 | -273,088 |
| Depreciation | 1,056 | 1,599 |
| Stock-based compensation expense | 19,024 | 35,395 |
| Amortization of premiums and discounts on marketable securities, net | 2,405 | 8,632 |
| Gain on disposal of property and equipment | -83 | - |
| Non-cash operating lease costs | 1,027 | 1,645 |
| Prepaid and other assets | 24,205 | 116,078 |
| Accounts payable | 5,782 | -4,670 |
| Operating lease liabilities | - | -1,919 |
| Accrued expenses and other liabilities | 35,140 | 31,891 |
| Accrued compensation | - | 14,782 |
| Operating right-of-use assets and lease liabilities, net | -2,031 | - |
| Deferred revenue | -2,339 | -5,420 |
| Net cash used in operating activities | -156,173 | -324,495 |
| Proceeds from maturities of marketable securities | 269,564 | 593,040 |
| Purchases of marketable securities | 853,603 | 243,271 |
| Purchases of property and equipment | 712 | 7,096 |
| Tenant improvements capitalized to right-of-use assets | 3,175 | - |
| Net cash used in investing activities | -587,926 | 342,673 |
| Proceeds from issuance of common stock in public offerings, net of issuance costs | 837,420 | 0 |
| Proceeds from issuance of common stock under employee incentive equity plans | 12,946 | 5,710 |
| Proceeds from the issuance of common stock in a private placement, net of issuance costs | 0 | 0 |
| Proceeds from issuance of pre-funded warrants in a private placement, net of issuance costs | 0 | 0 |
| Net cash provided by financing activities | 850,366 | 5,710 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | -16 | 154 |
| Net increase in cash, cash equivalents and restricted cash | 106,251 | 24,042 |
| Cash and cash equivalents at beginning of period | 222,663 | - |
| Cash and cash equivalents at end of period | 352,956 | - |
Avidity Biosciences, Inc. (RNA)
Avidity Biosciences, Inc. (RNA)